Edition:
United States

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

3.67USD
4:00pm EDT
Change (% chg)

$0.05 (+1.38%)
Prev Close
$3.62
Open
$3.62
Day's High
$3.67
Day's Low
$3.62
Volume
1,420
Avg. Vol
3,387
52-wk High
$9.32
52-wk Low
$2.59

Latest Key Developments (Source: Significant Developments)

Biomerica Says ‍Mexico's Cofepris' Approval Of EZ Detect Colorectal Screening Test​ - SEC Filing
Thursday, 8 Mar 2018 06:40am EST 

March 8 (Reuters) - Biomerica Inc ::BIOMERICA SAYS ‍MEXICO'S COFEPRIS' APPROVAL OF EZ DETECT COLORECTAL SCREENING TEST​ - SEC FILING.BIOMERICA SAYS APPOINTED DNA BIOPHARMA (DNA) AS EXCLUSIVE DISTRIBUTOR FOR EZ DETECT PRODUCT IN MEXICO.  Full Article

Xiamen Red Phase Instruments to acquire 5 pct stake in electronics technology firm for 30.5 mln yuan
Wednesday, 28 Feb 2018 09:34pm EST 

March 1(Reuters) - Xiamen Red Phase Instruments Inc <300427.SZ>:Says it plans to acquire 5 percent stake in a Shanghai-based electronics technology firm for 30.5 million yuan .  Full Article

Biomerica Q2 Loss Per Share $0.03
Tuesday, 16 Jan 2018 09:19am EST 

Jan 16 (Reuters) - Biomerica Inc ::BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER.Q2 LOSS PER SHARE $0.03.Q2 SALES ROSE 12.7 PERCENT TO $1.614 MILLION.  Full Article

China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer
Wednesday, 10 Jan 2018 08:19am EST 

Jan 10 (Reuters) - Biomerica Inc ::CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER.  Full Article

Biomerica extends license agreement with Celtis Pharm
Tuesday, 7 Nov 2017 08:19am EST 

Nov 7 (Reuters) - Biomerica Inc ::Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019.Biomerica Inc - has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea​.Biomerica - ‍term of exclusivity agreement is five years with an additional two years for telcon to receive Korean FDA clearance​.Biomerica - agreement may be cancelled if co has not obtained final clearance for sale of products in U.S. from FDA on or before December 31, 2019​.  Full Article

Biomerica Inc Q1 ‍net sales $1.4 million
Tuesday, 17 Oct 2017 08:19am EDT 

Oct 17 (Reuters) - Biomerica Inc :Net sales of $1.4 million for three months ending August 31, 2017, an increase of 2.4%​.Net loss for three months ended August 31, 2017 was $207,059 compared to a net loss of $55,417 during same period in fiscal 2017​.  Full Article

Biomerica announces point of care product distribution agreement with a multinational pharmaceutical company
Wednesday, 16 Aug 2017 08:19am EDT 

Aug 16 (Reuters) - Biomerica Inc :Biomerica announces point of care product distribution agreement with a multinational pharmaceutical company.Biomerica Inc - ‍distribution agreement to supply one of point of care products to a multinational pharmaceutical company for distribution in Mexico​.Biomerica inc - specific terms of distribution agreement were not disclosed and will remain confidential.  Full Article

Biomerica files for stock shelf of up to $45 mln
Friday, 30 Jun 2017 05:41pm EDT 

June 30 (Reuters) - Biomerica Inc ::Biomerica Inc files for stock shelf of up to $45 million - SEC filing.  Full Article

Biomerica reports Q3 net loss of $304,141
Monday, 17 Apr 2017 08:19am EDT 

April 17 (Reuters) - Biomerica Inc :Biomerica announces third quarter financial results, sales up 13.9 pct for nine months.Q3 sales $1.5 million versus $1.362 million.Net loss for 3 months ended February 28, 2017 was $304,141 compared to a net loss of $135,002 during three months ended February 29, 2016.  Full Article

Xiamen Red Phase Instruments sees Q1 FY 2017 net loss to be 5 mln yuan to 6.5 mln yuan
Thursday, 23 Mar 2017 01:59am EDT 

Xiamen Red Phase Instruments Inc <300427.SZ> : Sees Q1 FY 2017 net loss to be 5 million yuan to 6.5 million yuan . Says Q1 FY 2016 net loss was 5.8 million yuan .The reason for the forecast is seasonal effect.  Full Article

BRIEF-Biomerica Q3 Sales $1.376 Million Versus $1.5 Million

* Q3 SALES $1.376 MILLION VERSUS $1.5 MILLION Source text for Eikon: Further company coverage: